|1.||Centanni, S: 4 articles (06/2003 - 01/2000)|
|2.||Kalberg, C: 4 articles (08/2001 - 06/2000)|
|3.||Edwards, L: 4 articles (07/2001 - 06/2000)|
|4.||Antileukotriene Working Group: 4 articles (06/2001 - 06/2001)|
|5.||Kamei, Chiaki: 3 articles (11/2007 - 01/2004)|
|6.||Allegra, L: 3 articles (05/2003 - 01/2000)|
|7.||Nathan, R A: 3 articles (08/2001 - 06/2001)|
|8.||Yancey, S W: 3 articles (07/2001 - 01/2001)|
|9.||Rickard, K A: 3 articles (07/2001 - 06/2000)|
|10.||Rickard, K: 3 articles (07/2001 - 11/2000)|
|1.||Asthma (Bronchial Asthma)
01/01/2014 - "It has proven efficacy in reducing asthma exacerbations, but the effect size of zafirlukast for asthma exacerbations of various severity is not systematically explored. "
04/01/2002 - "Furthermore, good efficacy of zafirlukast was confirmed in clinical trials in adult bronchial asthma patients. "
04/01/2000 - "This study has demonstrated that zafirlukast offers significant protection against cold air-induced bronchoconstriction in asthma. "
01/01/2008 - "In Group I, zafirlukast significantly improved morning PEF and FEV1compared to placebo (p < 0.01), and reduced morning waking with asthma from baseline after two weeks (p < 0.05). "
03/01/2001 - "In conclusion, we demonstrate the efficacy of zafirlukast in asthma therapy particularly for those patients who are younger and have better pulmonary function. "
10/01/2012 - "The present study suggests that zafirlukast may be effective in reducing breast capsule distortion in patients with long-standing contracture, though reduced capsular contracture values are strictly related to the duration of drug intake."
01/01/2005 - "Zafirlukast appears effective in treating early capsular contracture after primary submuscular breast augmentation using saline-filled, smooth-walled implants. "
07/01/2007 - "Effects of zafirlukast on capsular contracture: controlled study measuring the mammary compliance."
01/01/2005 - "The purpose of this study was to prospectively examine a single surgeon's experience using zafirlukast in the treatment of capsular contracture in primary, submuscular breast augmentation with saline-filled, smooth-walled implants. "
10/01/2012 - "Effects of zafirlukast on capsular contracture: long-term results."
|3.||Chronic Obstructive Pulmonary Disease (COPD)
01/01/2000 - "Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist."
05/01/2013 - "The aim of our study was to evaluate the effects of Zafirlukast improvement of lung function in patients with COPD. "
01/01/2003 - "Through a randomised, double-blind, crossover and placebo-controlled study, we assessed the short-term effects of zafirlukast in patients with severe COPD. "
05/01/2013 - "Results showed that Zafirlukast has no considerable bronchodilatory effect in COPD. "
03/01/2003 - "Zafirlukast may play a role as an alternative to decrease PAP in COPD patients."
06/01/2003 - "At the end of the study period, zafirlukast significantly reduced asthma and rhinitis symptoms (P< or =0.05); FEV(1) values were unchanged (P=0.10), whereas nasal resistances showed a decrease following treatment (P=0.01). "
09/01/1997 - "All available published articles describing double-blind, placebo-controlled trials of both oral and aerosol zafirlukast in patients with asthma or rhinitis were reviewed. "
06/01/2003 - "These positive effects suggest that zafirlukast may be usefully employed in the treatment of both bronchial asthma, as previously demonstrated, and allergic rhinitis."
06/01/2003 - "Effects of zafirlukast on bronchial asthma and allergic rhinitis."
07/01/2007 - "We performed a placebo-controlled study, with 120 persistent, moderate to severe allergic rhinitis patients randomly selected to receive the different treatments for 4 weeks: no treatment, 10 mg of cetirizine once per day, 20 mg of zafirlukast once per day, 20 mg of cafirlukast twice per day, a combination of 20 mg of zafirlukast and 10 mg of cetirizine once per day, or a combination of 20 mg of zafirlukast twice per day and 10 mg cetirizine once per day. "
06/01/1998 - "In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma. "
05/11/2001 - "A recent clinical study showed that combined antagonists loratadine (H1) and zafirlukast (CysLT1) were more effective against allergic bronchospasms than either drug alone. "
04/01/1990 - "Aerosol ovalbumin antigen-induced bronchospasm in guinea pigs was both inhibited and reversed by ICI 204,219. "
|2.||Leukotriene Receptors (Leukotriene Receptor)
|7.||Adrenal Cortex Hormones (Corticosteroids)
|9.||leukotriene D4 receptor (cysteinyl leukotriene receptor)
|10.||Leukotriene Antagonists (Leukotriene Receptor Antagonists)
|2.||Drug Therapy (Chemotherapy)